Abstract
Multiple sclerosis (MS) treatment via cytokine-mediated immunomodulation has been hampered by the difficulty with which cytokines can be stably and noninvasively delivered to the central nervous system. Here, we show that interleukin (IL)-13 packaged in extra-large-pore mesoporous silica nanoparticles (XL-MSNs) is protected from degradation and directs the alternative activation of macrophages bothin vitroandin vivo. Furthermore, the noninvasive intranasal delivery of IL-13-loaded XL-MSNs ameliorated the symptoms of experimental autoimmune encephalomyelitis, a murine model of MS, accompanied by the induction of chemokines orchestrating immune cell infiltration. These results demonstrate the therapeutic potential of IL-13-loaded XL-MSNs for MS patients.
| Original language | English |
|---|---|
| Pages (from-to) | 4446-4453 |
| Number of pages | 8 |
| Journal | ACS Biomaterials Science and Engineering |
| Volume | 7 |
| Issue number | 9 |
| DOIs | |
| State | Published - 13 Sep 2021 |
Keywords
- autoimmune disease
- cytokine
- intranasal delivery
- multiple sclerosis
- nanomaterials
Fingerprint
Dive into the research topics of 'Alternative Activation of Macrophages through Interleukin-13-Loaded Extra-Large-Pore Mesoporous Silica Nanoparticles Suppresses Experimental Autoimmune Encephalomyelitis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver